# Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Source: https://onco.cc/trials/nct03562637/  
OnCo record `nct03562637` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Adagloxad simolenin run by OBI Pharma, Inc, active.

## Summary

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC is a phase 3 interventional study registered as NCT03562637 by OBI Pharma, Inc, with 575 participants enrolled, started 2018-12-05. Conditions listed: Triple Negative Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03562637
- Phase: 3
- Setting: The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer
- Sponsor: OBI Pharma, Inc
- Enrolled: 575

## Sources

- ClinicalTrials.gov NCT03562637: https://clinicaltrials.gov/study/NCT03562637

## Connected records

- drugs: [Adagloxad simolenin](https://onco.cc/drugs/adagloxad-simolenin/)

---
JSON: https://onco.cc/api/v1/entities/nct03562637.json